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Background: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core
30 (EORTC QLQ-C30) is the instrument most frequently used to measure quality of life in cancer patients, whereas
the EQ-5D is widely used to measure and evaluate general health status. Although the EORTC QLQ-C30 has been
mapped to EQ-5D utilities, those studies were limited to patients with a single type of cancer. The present study
aimed to develop a mapping relationship between the EORTC QLQ-C30 and EQ-5D-based utility values at the
individual level.
Methods: The model was derived using patients with different types of cancer who were receiving chemotherapy.
The external validation set comprised outpatients with colon cancer. Ordinary least squares regression was used to
estimate the EQ-5D index from the EORTC QLQ-C30 results. The predictability, goodness of fit, and signs of the
estimated coefficients of the model were assessed. Predictive ability was determined by calculating the mean
absolute error, the estimated proportions with absolute errors > 0.05 and > 0.1, and the root-mean-squared
error (RMSE).
Results: A model that included global health, physical, role, emotional functions, and pain was optimal, with a
mean absolute error of 0.069 and an RMSE of 0.095 (normalized RMSE, 8.1%). The explanatory power of this model
was 51.6%. The mean absolute error was higher for modeled patients in poor health.
Conclusions: This mapping algorithm enabled the EORTC QLQ-C30 to be converted to the EQ-5D utility index to
assess cancer patients in Korea.
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In addition to assessing of clinical efficacy, appraisals of
new healthcare technology need to assess cost-effective-
ness. Cost-utility analysis is frequently used for eco-
nomic evaluation, with outcomes evaluated in terms of
quality-adjusted life years, a measure that combines both
the length and quality of life. Utilities are preference-
based and derived from each individual, either directly
using valuation techniques such as standard gamble,
time trade-off, or the use of a rating scale, or indirectly
using generic health-related quality of life (HRQoL)
measures, such as the Health Utility Index [1,2], the
EuroQol 5D (EQ-5D), [3] or the Short Form 6D [4].
Scoring algorithms have been developed for all of these* Correspondence: jominwoo@amc.seoul.kr
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reproduction in any medium, provided the ormeasures, which provide community-based health utility
estimates [5].
HRQoL is often used as a secondary endpoint in can-
cer trials. Studies measuring patient quality of life often
prefer disease-specific instruments over generic instru-
ments. The former focus on particular health problems
and tend to be more sensitive to clinically important dif-
ferences [6]. They do not, however, include utility scor-
ing systems. Therefore, the development of a tool that
can map disease-specific measures onto preference-
based measures may also generate weighted utilities.
The European Organisation for Research and Treat-
ment of Cancer Quality of Life Questionnaire Core 30
(EORTC QLQ-C30) is the instrument most frequently
used to measure the quality of life of cancer patients [7].
The Korean version of the EORTC QLQ-C30 has been
validated for use in Korean cancer patients [8]. Although. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from the EORTC QLQ-C30, was recently introduced
[9], the results obtained from these questionnaires can-
not be compared with the results of questionnaires
based on other disease areas because the EORTC QLQ-
C30 is a cancer-specific instrument. Moreover, to our
knowledge, no valuation set for the EORTC-8D has yet
been developed in Korea. The EQ-5D, an instrument
widely used to measure and evaluate general health sta-
tus, can also be used to assign preference values to these
health states. Population tariffs using the EQ-5D have
been developed in several countries, including Korea
[10,11]. Although the EORTC QLQ-C30 has been
mapped onto EQ-5D utilities [5,12-14], those studies
were limited to patients with a single type of cancer.
The purpose of this study was to develop a mapping
relationship between the EORTC QLQ-C30 and EQ-5D-
based utility values at the individual level for patients
with a wide range of cancers.
Methods
Data set and instruments
We used two data sets to formulate the mapping algo-
rithm for the EORTC QLQ-C30 and the EQ-5D. The
derivation set comprised 893 patients with different
types of cancer [15], whereas the external validation set
comprised 123 patients with colon cancer [16]. The
patients in these two studies were independent of each
other, but were recruited at the same cancer center.
The EQ-5D comprises five dimensions that measure
general health status: mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression, with each di-
mension having three levels. Thus, the EQ-5D provides
a simple descriptive profile and a single utility index of
health status, which can be used in the clinical and eco-
nomic evaluation of healthcare, as well as for population
health surveys [10]. The EQ-5D index for use in Korea
was calculated using an algorithm [11], with possible
scores ranging from −0.171 to 1.0, with 1.0 indicating
full health (11111 state) and 0.0 denoting death.
The EORTC QLQ-C30 is an integrated system that
assesses the HRQoL of cancer patients. It includes five
functional scales (physical, role, emotional, cognitive,
and social), three symptom scales (fatigue, nausea or
vomiting, and pain), global health status, and six single
items (dyspnea, insomnia, appetite loss, constipation,
diarrhea, and financial difficulties) [7]. All of these scales
and items were linearly transformed from 0 to 100
according to the EORTC QLQ-C30 scoring rules [17].
High scores on the functional scales indicate a high level
of functioning and high scores on the global health sta-
tus indicate a high quality of life; by contrast, high scores
on the symptom scales/items indicate high levels of
health problems [17].Analysis
Ordinary least squares (OLS) regression was used to es-
timate the EQ-5D index from the EORTC QLQ-C30.
The dependent variable was the EQ-5D index, and the
explanatory variables were the EORTC QLQ-C30 scale
and item scores. All variables were treated as continuous
variables. The full model, which included the scores for
all scales and items in the EORTC QLQ-C30, was
explored and another model was developed using back-
ward elimination with a significance level of 0.1 from
the full model.
The relationships between the observed and predicted
values were assessed visually. The performance of each
model was evaluated by determining its predictability,
goodness of fit, and the signs of the estimated coeffi-
cients. The purpose of a mapping function is to predict
health utility values in other data sets; therefore, the
model was assessed according to the accuracy of its pre-
dictions [18]. Predictive ability was determined by calcu-
lating the mean absolute error (MAE), the estimated
proportions with absolute errors > 0.05 and >0.1, and
the root-mean-squared error (RMSE). The MAE is the
average of the absolute differences between the observed
and predicted values, and the RMSE is the root of the
average of the squared differences. RMSE can also be
reported as a percentage of the scale size (i.e., 1.171, the
range of the EQ-5D-based utility according to the Ko-
rean algorithm [11]), referred to as the normalized
RMSE [19]. Smaller MAE and RMSE values indicate bet-
ter model performance. The important aspect of the
mapping was the estimated group mean and its variance,
rather than individual estimated utilities. To determine
whether errors were affected by disease severity, both
the highest and the lowest EQ-5D index quartile groups
of the derivation and validation sets were evaluated sep-
arately. The overall equality of the coefficients of the
good health group and other groups was tested using the
likelihood ratio test. In addition, the adjusted R2 values
and the signs of the estimated coefficients were calcu-
lated. The sign of the functional scales was expected to
be positive, while that of the symptom scales/items was
expected to be negative.
Statistical analyses were performed using SAS software
(ver. 9.1; SAS Institute Inc., Cary, NC). P<0.05 was con-
sidered statistically significant.
Results
The derivation set included patients with 28 different
types of cancer (Table 1). Breast cancer was the most
common (32.9%), followed by colorectal cancer (20.0%).
Table 2 presents the descriptive statistics for the EQ-5D
index and the EORTC QLQ-C30 scales of the derivation
and validation sets. Patients in the derivation set gener-
ally had poorer scores on all scales (except for diarrhea)
Table 1 Distribution of cancer patients in the derivation
set






Bone marrow 31 (3.5)
Liver 31 (3.5)
Lymph node 23 (2.6)
Esophagus 20 (2.3)
Gall bladder 14 (1.6)
The others (18 types) 71 (8.0)
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scale and item scores were statistically significant, except
for “constipation” and “financial difficulty”.
The results of the OLS regression analysis of each of
the two models are shown in Table 3, and model per-
formance is shown in Table 4. In Model 2 (i.e., the back-
ward elimination model), the five scales were statistically
significant; the emotional functioning scale, which had a




EQ-5D index 893 0.824 (0.137)
EORTC QLQ-C30 functional scales
Global health status* 893 59.8 (21.9)
Physical functioning* 893 72.1 (18.3)
Role functioning* 893 68.2 (27.1)
Emotional functioning* 893 70.9 (23.2)
Cognitive functioning* 892 76.5 (20.8)
Social functioning* 893 62.8 (28.2)
EORTC QLQ-C30 symptom scales/items
Fatigue* 893 40.6 (22.0)
Nausea and vomiting* 893 22.5 (25.5)
Pain* 893 28.8 (26.2)
Dyspnea* 892 24.4 (26.8)
Insomnia* 889 31.3 (30.6)
Appetite loss* 889 31.8 (31.4)
Constipation 892 26.1 (29.3)
Diarrhea* 892 18.7 (26.0)
Financial difficulties 892 37.9 (33.3)
*p < 0.05; Student’s t test.significant in Model 2, with a p value of 0.01. Physical
functioning was the most influential scale in both mod-
els (Table 3). The explanatory power of Model 2 was
51.6%. The MAE values of both models were the same:
0.095 for the derivation set and 0.066 for the validation
set. In Model 2, the normalized RMSE was 8.1% for the
derivation set and 7.2% for the validation set. The pro-
portion of AEs > 0.1 in Model 2 was 23.1% for the deriv-
ation set and 24.4% for the validation set. The actual
mean value of the EQ-5D index was similar to the pre-
dicted EQ-5D indices of both models (Table 4). Figure 1
shows a plot of the predicted value based on Model 2
versus the observed EQ-5D index in both the derivation
and validation sets. In both sets, EQ-5D index for values
below 0.7 tended to be overestimated, whereas the max-
imum value of EQ-5D was underestimated.
Table 5 shows the model performance for both the
derivation and validation sets according to health status
when Model 2 was fitted. The MAEs of the lowest quar-
tile group on the EQ-5D for the derivation (≤0.723) and
validation (≤0.817) sets were 0.100 and 0.060 respect-
ively, whereas the MAEs of the highest quartile group
on the EQ-5D for the derivation (≥0.907) and validation
(≥1) sets were 0.067 and 0.060, respectively. The regres-
sion coefficients of the lowest and highest quartile
groups were not equal overall (p=0.021). In both data
sets, the mean predicted value was overestimated in theTC QLQ-C30 scales used in the derivation and validation
Validation set (n = 123)
Median (IQR) Mean (SD) Median (IQR)
0.854 (0.723–0.907) 0.871 (0.113) 0.87 (0.817–1.000)
66.7 (25.0–50.0) 68.2 (22.5) 66.7 (50.0–83.3)
73.3 (60.0–86.7) 79.2 (16.0) 80.0 (73.3–93.3)
66.7 (50.0–100) 77.2 (21.9) 83.3 (66.7–100)
75.0 (58.3–91.7) 79.8 (21.1) 83.3 (66.7–100)
83.3 (66.7–100) 80.5 (19.4) 83.3 (66.7–100)
66.7 (50.0–83.3) 73.2 (23.0) 66.7 (66.7–100)
33.3 (22.2–55.6) 33.0 (19.8) 33.3 (22.0–44.4)
16.7 (0.0–33.3) 14.9 (21.8) 0.0 (0.0–16.7)
16.7 (0.0–50.0) 17.1 (21.2) 16.7 (0.0–33.3)
33.3 (0.0–33.3) 17.9 (21.9) 0.0 (0.0–33.3)
33.3 (0.0–33.3) 19.5 (23.7) 0.0 (0.0–33.3)
33.3 (0.0–66.7) 18.4 (24.2) 0.0 (0.0–33.3)
33.3 (0.0–33.3) 20.9 (26.8) 0.0 (0.0–33.3)
0.0 (0.0–33.3) 27.4 (28.6) 33.3 (0.0–33.3)
33.3 (0.0–66.7) 31.7 (30.1) 33.3 (0.0–66.7)
Table 3 Ordinary least squares regression model
Model 1a Model 2b
β SE p value β SE p value
Intercept 0.53897 0.03507 < 0.0001 0.56317 0.02044 < 0.0001
Global health status 0.00092 0.00018 < 0.0001 0.00097 0.00018 < 0.0001
Physical functioning 0.00223 0.00027 < 0.0001 0.00222 0.00026 < 0.0001
Role functioning 0.00065 0.00019 0.001 0.00067 0.00018 0.0001
Emotional functioning 0.00038 0.00021 0.071 0.00045 0.00017 0.01
Cognitive functioning 0.00015 0.00021 0.474
Social functioning 0.0002 0.00017 0.234
Fatigue 0.00042 0.00027 0.111
Nausea and vomiting −0.00005 0.00015 0.737
Pain −0.00123 0.00017 < 0.0001 −0.00125 0.00016 < 0.0001
Dyspnea −0.00024 0.00015 0.102
Insomnia −0.00009 0.00013 0.494
Appetite loss −0.00001 0.00014 0.943
Constipation −0.00004 0.00012 0.72
Diarrhea 0.00005 0.00013 0.72
Financial difficulties 0.00005 0.00012 0.673
aModel 1 included all functioning and symptom scales and items of the EORTC QLQ-C30 as explanatory variables.
bModel 2 applied backward elimination to Model 1.
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quartile group.
Discussion
This study explored an algorithm for mapping the EORTC
QLQ-C30 onto the EQ-5D index. Model 2, which includedTable 4 Comparison of the performance of Models 1 and 2
Model 1a Model 2b
Derivation set
Adjusted R2 0.511 0.516
RMSE (% RMSE) 0.095 (8.1) 0.095 (8.1)
MAE (SD) 0.069 (0.065) 0.069 (0.066)
MAE > 0.05(%) 48.7 50.1
MAE > 0.1(%) 22.4 23.1
EQ-5D index Actual Predicted Predicted
Mean (SD) 0.824 (0.137) 0.823 (0.098) 0.824 (0.098)
Validation set
RMSE (% RMSE) 0.083 (7.1) 0.085 (7.2)
MAE (SD) 0.066 (0.052) 0.066 (0.053)
MAE > 0.05(%) 53.7 49.6
MAE > 0.1(%) 23.6 24.4
EQ-5D index Actual Predict Predict
Mean (SD) 0.871 (0.113) 0.873 (0.083) 0.872 (0.085)
aModel 1 included all functioning and symptom scales and items of the EORTC
QLQ-C30 as explanatory variables.
bModel 2 applied backward elimination to Model 1.global health status, physical functioning, role functioning,
emotional functioning, and pain as explanatory variables,
was preferred over the full model, due to its predict-
ability, logical consistency, and parsimony. Although map-
ping the EORTC QLQ-C30 onto the EQ-5D index has
been assessed previously, those studies evaluated patients
with specific types of cancer, including gastric [5], esopha-
geal [13], and breast [12,14] cancers and multiple myeloma
[19]. By contrast, the present study evaluated patients with
28 different types of cancer, providing our mapping model
with the advantage (over earlier mapping algorithms) of
being applicable to all cancer patients in Korea.
We also explored models using only functional scales
as explanatory variables and a backward elimination
model of the functional scale (data not shown). We
found that Model 2 showed optimum performance,
retaining the global health, physical, role, emotional
functioning, and pain scales. The MAE of this model,
0.066, was lower than the MAE of 0.092 reported in an-
other Korean study [14]. The adjusted R2 of our deriv-
ation set was 0.516 and the normalized RMSE was 8.1%.
We also analyzed our data based on the UK tariff [20]
using backward elimination regression. Although the
remaining variables were the same as those using the
Korean tariff, the magnitude of the absolute coefficients
increased. The MAE of the UK backward elimination
model for our derivation set was 0.156, and the adjusted
R2 was 0.463. A systematic review reported that R2 sta-
tistics for condition-specific measures relative to generic
Figure 1 Scatter plot of predicted values based on Model 2 parameters versus the actual EQ-5D index. A perfect fit is indicated by the
45° reference line.
Kim et al. Health and Quality of Life Outcomes 2012, 10:151 Page 5 of 6
http://www.hqlo.com/content/10/1/151measures generally ranged from 0.4–0.6 [18]. Another
study showed that the backward regression model
resulted in better predictability than the full model, with
the former showing an adjusted R2 of 0.8 and a normal-
ized RMSE of 6.02% for the derivation set; that study,
however, included squared terms, such as the square of
the physical functioning scale [12]. Use of OLS with a
stepwise regression model retaining three scales (global
health, physical, and emotional functioning) yielded an
adjusted R2 of 0.611 and a normalized RMSE of 12.0%
for the derivation set [5]. Application of OLS regression
using all of the scale scores in patients with esophageal
cancer resulted in variables slightly different from thoseTable 5 Performance in Model 2 according to EQ-5D
quartile in the derivation and validation sets
Derivation set Validation set
The lowest quartile
N 224 33
RMSE (% RMSE) 0.137 (11.7) 0.119 (10.2)
MAE (SD) 0.100 (0.093) 0.060 (0.057)
EQ-5D index Actual Predict Actual Predict
Mean (SD) 0.647 (0.125) 0.726 (0.093) 0.723 (0.070) 0.806 (0.086)
The highest quartile
N 267 37
RMSE (% RMSE) 0.087 (8.7) 0.003 (0.27)
MAE (SD) 0.067 (0.055) 0.060 (0.049)
EQ-5D index Actual Predict Actual Predict
Mean (SD) 0.960 (0.045) 0.902 (0.057) 1.000(0.000) 0.940 (0.049)previously reported, including global health, role, emo-
tional, cognitive function, pain, and fatigue, with an
adjusted R2 of 0.611 for the derivation set [13].
OLS regression tends to overestimate the true value of
EQ-5D utilities for patients in poor health, while under-
estimating the true EQ-5D utilities at the upper end of
the scale [14,21,22]. Our model showed the same trend,
overpredicting the mean EQ-5D index in the group of
patients in relatively poor health. The MAE of the best
performing model increased from 0.056 in the relatively
healthy group to 0.078 in the group with relatively poor
health. Caution is therefore warranted when applying a
mapping function to patients in poor health, and further
research is needed regarding the cut-off points for the
use of the EORTC QLQ-C30 on patients in poor health.
Mapping is the second best alternative to the direct use
of a preference-based measure because mapped esti-
mates can yield large errors, particularly when mapping
from condition-specific to generic preference-based
measures [18]. This, however, may not be as important
for QLQ C-30 mappings.
The mapping algorithm formulated in this study may
have limited generalizability, because the participants in
the validation set came from only one hospital. Although
our sample included individuals with various conditions,
further research with samples from other institutions
would be helpful.
Conclusions
The mapping model using OLS regression showed a rea-
sonable predictive ability. This mapping algorithm may
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QLQ-C30 to the EQ-5D utility indexes for Korean can-
cer patients. Nevertheless, using OLS regression to pre-
dict very low and high EQ-5D indices remains
challenging. These findings may help when assessing the
performance of cost-utility analyses of the use of health-
care interventions in cancer patients.
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